Current treatment options for opioid and other forms of addiction do not work for most people. What’s missing is the ability to fast track the withdrawal process. Ibogaine – a molecule found in Tabernanthe iboga and other plants – offers the opportunity for a rapid detox. In combination with an effective therapeutic setting, ibogaine offers the opportunity to live free from addiction. Our goal is to provide safe, effective and affordable ibogaine treatment internationally this decade.
Why go public now? To enable public participation in an ibogaine-focused company incorporating:
Clinical Trials Application to Commence
Conventional Detox Clinics in Operation in 2021
Phase 2 Clinical Trials begin in 2022
Phase 3 Clinical Trials begin in Q3 2022
Our balance of medical expertise, clinic operations, and capital markets relationships puts us on a path for success.
Financials will be available once they are filed and we are a fully reporting publicly traded company.
We have completed a Subscription Receipt Qualifying Transaction, we aim to be publicly trading in September 2021.
Being publicly owned allows everyone to be a part of the solution and enables us to obtain required funding for clinical trials in Canada and overseas
Board of Directors
Chief Ian Campbell, MBA
Dr. Alberta Sola, Ph.D
CoFounder & Director
Robert Turner, MBA
Connect with Us
P SQUARED RENEWABLES INC. ANNOUNCES THE COMPLETION OF QUALIFYING TRANSACTION AND THE PRIOR CLOSING OF $6 MILLION SUBSCRIPTION RECEIPT FINANCING
Universal Ibogaine and PSQ are pleased to announce the completion of the Qualifying Transaction, closing the $6 million subscription receipt financing.
Universal Ibogaine and PSQ are pleased to announce that PSQ has SEDAR filed…
P SQUARED RENEWABLES INC. AND UNIVERSAL IBOGAINE INC. ANNOUNCE TSX.V CONDITIONAL APPROVAL OF QUALIFYING TRANSACTION
Calgary, Alberta – P Squared Renewables Inc. (TSXV: PSQ.P) (“PSQ” or the “Company“) a capital